ctDNA-Guided Pembrolizumab Clears Minimal Residual Disease and Reduces Recurrence in dMMR Solid Tumors Post-Surgery: Phase 2 Trial Results.

A recent phase 2 trial investigated using circulating tumor DNA (ctDNA) to guide adjuvant pembrolizumab therapy after surgery. The study focused on patients with resected mismatch repair-deficient (dMMR) solid tumors and found that this approach effectively cleared minimal residual disease. Furthermore, the trial reported a reduction in cancer recurrence among participants. Specifically, researchers designed the trial to assess whether ctDNA, a type of genetic material released by cancer cells into the bloodstream, could help personalize adjuvant pembrolizumab treatment. Adjuvant therapy refers to treatment given after surgery to eliminate any remaining cancer cells. The trial enrolled patients who had undergone surgery for dMMR solid tumors, a type of cancer characterized by a deficiency in the mismatch repair system. The findings indicated that using ctDNA to guide pembrolizumab therapy led to the clearance of minimal residual disease, which is the small number of cancer cells that may remain after initial treatment. The trial also demonstrated a decrease in the recurrence of cancer in these patients.

Newsflash | Powered by GeneOnline AI
Date: April 28, 2025

Related posts:

Real-Time Brain Imaging Unveils Neural Processing of Stimuli AI-driven biomanufacturing: revolutionising production and quality in pharmaceuticals Teenagers Spending Over 3 Hours Daily on Screens Linked to Increased Anxiety and Depression: Study of 500 Teens Webinar: How Fintech Can Accelerate Growth for Early-Stage Life Science Companies

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後